Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Acta Mater Med. 2022 Jan 21;1(1):24–41. doi: 10.15212/amm-2021-0001

Figure 4. E3 ligase ligands that are commonly used for PROTACs.

Figure 4.

Derivatives of Thalidomide targeting Cereblon (CRBN) and the ligand of Von Hippel Lindau (VHL). The asterisk shows the point of attachment to the linker.